# Research Pulse — 2026-07-07 _Generated 2026-07-07 07:30 KST · AI × Bioresearch Daily synthesis_ Brown Biotech daily research pulse — multi-front synthesis across CRISPR / gene editing, AI drug discovery, protein AI, single-cell foundation models, FDA/regulatory, and spatial transcriptomics. Sources: company filings, peer-reviewed journals, FDA guidance, conference disclosures. --- ### Post 1: 오늘의 전체 흐름 🧬 **AI × Bioresearch Daily — 7월 7일 (화요일) · 확장의 날(Expansion Day)** 6/14(전환)→6/15(구현)→6/16(수렴)→6/17(이행)→6/18(심화)→6/19(통합)→6/20(확산)→6/21(안착)→6/22(현장화)→6/24(확산)→6/25(통합)→6/27(종합)→6/29(이행)→6/30(이행 심화)→7/1(이행 확산)→7/2(제도화)→7/4(표준화)→7/5(표준 이행)→7/6(통합)→오늘 확장의 날(Expansion Day). 통합된 기준들이 산업 전반으로 확산(Expansion)되는 날 — 임상 이행과 규제 확장이 핵심 동사. Organoid-free LNP delivery(>80% knock-kout, Streiber Small 2026)와 PEG-free organic solvent-free LNP(장기 간 이행 가능, extrahepatic targeting, Streiber)가 CRISPR delivery의 임상적 확장 가능성을 실증하고, hypoimmune iPSC(CRISPR으로 HLA class I/II 제거 + immune-tolerant molecules 유지, Wu Stem Cell Res Ther 2026)가 범용 세포 치료 확장을 제시하며, MONSTAR-SCREEN-3(331개 종양, 21개 고형암, ~2천만 개 세포, Xenium 5K)이 공간 전사체 확장의 산업 표준을 제시하고, AlphaFold 4(DeepMind drug spin-off, Nature 2026) 발표와 AlphaFold 3 transformative review(Frontiers AI 2026)가 단백질 구조 확장의 새 시대를 열며, TAM pan-cancer atlas(28개 subtypes, 16개 암종, 291개 샘플, Cell Discovery 2026)가 종양 면역 확장 분석의 스케일을 한 단계 올린다. 확장은 통합의 다음 단계다. 오늘 6개 전선은 통합된 기준들이 산업 전반으로 확장되며 임상 이행과 규제 확장이 동시에 가속하는 날이다. *출처: [Extrahepatic LNP Streiber Small 2026](https://consensus.app/papers/details/1ba8360a176b5f83913089048aa90b2e/), [Hypoimmune iPSC Wu Stem Cell Res Ther 2026](https://consensus.app/papers/details/1cba919e589f54adaa8363be5f6ee23b/), [MONSTAR-SCREEN-3 AACR 2026](https://consensus.app/papers/details/acaee5f0a8c55ba89f5719ee65eaba95/), [AlphaFold 4 DeepMind Nature 2026](https://consensus.app/papers/details/30239e12756b5c63ab7b87a66091fe4b/), [AlphaFold 3 Review Chakraborty Front AI 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/), [TAM Atlas Nie Cell Discovery 2026](https://consensus.app/papers/details/cae4940d39b251569b9f7f6e65465aad/)* --- ### Post 2: CRISPR & Delivery — Organoid-free LNP delivery(>80% knockout) + Hybrid piggyBac+AAV+LNP(100배 감량) + PEG-free LNP(extrahepatic): CRISPR delivery 확장의 세 가지 실증 🧪 **[CRISPR/Delivery] Organoid-free LNP delivery(>80% knockout, Small 2026) + Hybrid piggyBac+AAV+LNP(100배 감량, Molecular Therapy 2026) + PEG-free organic solvent-free LNP(extrahepatic targeting, Small 2026): CRISPR delivery 확장 — 산업적 확장 가능성의 세 가지 동시 실증** CRISPR delivery의 **확장**이 세 논문에서 동시에 실증된다. Jiang et al.(Small 2026), Xu et al.(Molecular Therapy 2026), Streiber et al.(Small 2026)의 논문이 각각 다른 축을 제시한다[1][2][3]. **LNP compositional optimization: >80% knockout[1]**: (1) **Ionizable lipid library**: 4A2C2C6-A8과 4A2C2C8-A8의 molar ratio variation으로 formulation library 구성. (2) **최적화 결과**: HeLa-Luc cells에서 >80% knockout 달성. (3) **물리화학적 특성**: high zeta potential, ~200nm mean diameter, appropriate internal hydrophobicity. (4) **Mechanism**: superior cellular uptake + endosomal escape capabilities의 synergistic effect. (5) **적용 사례**: HSP47 knock-kout(L929 cells, fibrosis 치료) → codeliver Cas9 mRNA + sgRNA. (6) **핵심**: CRISPR/Cas9 LNPs의 formulation optimization 가이드라인 확립. **Hybrid piggyBac+AAV+LNP: 100배 dose reduction[2]**: (1) **문제의식**: AAV gene therapy는 고독성(dose-dependent toxicity) + early-life administration 시 durability 문제. (2) **Hybrid 접근**: AAV9로 hARG1 transposon 전달 + LNP로 super piggyBac(SPB) transposase mRNA 전달. (3) **결과**: 5×10¹¹-1×10¹³ gc/kg로 9개월 survival(vehicle는 50일 내 사망). (4) **AAV-alone 대비**: 100배 낮은 dose로 동등한 효과 달성. (5) **Durability**: adult conditional Arg1 knockout mice에서 장기적 안정성 확인. (6) **핵심 혁신**: LNP-mediated transient transposase delivery로 AAV의 dose toxicity 해결. **PEG-free organic solvent-free LNP: extrahepatic targeting[3]**: (1) **PEG/Ethanol 문제**: immune response 유발, PEGylation의 비的可역적 특성. (2) **물절적 formulation**: purely water-based LNP, PMeOx(stealth lipid) + approved lipids. (3) **장점**: material-efficient, time-saving, high reproducibility. (4) ** Immune evasion**: primary human immune cells 효과적 transfection. (5) **핵심 차별점**: conventional cholesterol-rich LNPs와 달리 **extravascular/extrahepatic tissue transfection 가능**. (6) **향후**: repeated dosing + targeted applications 위한 새로운 가능성. **7월 6일 Cas9 Delivery 통합(LNP + split-intein + high-fidelity) vs 오늘의 차별점**: 7/6이 **LNP + split-intein + high-fidelity + viral/non-viral hybrid의 cross-domain delivery 통합**을 제시했다면, 오늘은 그와 다른 축 — **delivery 확장 가능성의 산업적 실증**을 동시에 세 논문에서 제시한다. hybrid piggyBac로 100배 dose reduction, PEG-free LNP로 extrahepatic targeting 실현, compositional optimization으로 >80% knockout 달성. 통합(7/6) → 확장 실증(7/7). 실무 함의: 유전체 편집 플랫폼팀에서 Jiang et al.의 LNP formulation optimization 가이드라인을 참조하여 자사의 CRISPR/Cas9 delivery pipeline을 최적화해야 한다. Gene therapy 개발팀에서 hybrid piggyBac+AAV+LNP 접근으로 AAV dose toxicity 문제를 해결하고 durability를 확보해야 한다. 면역거부 최소화 목표에서 Streiber et al.의 PEG-free organic solvent-free LNP를 활용하여 repeated dosing 전략을 수립해야 한다. *출처: [LNP Optimization Jiang Small 2026](https://consensus.app/papers/details/88fb6c79e4d859f389cdf3480a9815be/), [Hybrid piggyBac AAV LNP Xu Molecular Therapy 2026](https://consensus.app/papers/details/0c2389f227c5528993ce96984aeb2036/), [Extrahepatic LNP Streiber Small 2026](https://consensus.app/papers/details/1ba8360a176b5f83913089048aa90b2e/), [Nanomaterial CRISPR Delivery Wang Frontiers 2026](https://consensus.app/papers/details/f43692af0ccb54b684ef6714b3de8d82/)* *#LNPOptimization #CRISPRDelivery #LipidNanoparticle #AAV #PiggyBac #Extrahepatic #PEGfree #OrganicSolventFree #DoseReduction #100x #HSP47 #Fibrosis #MolecularTherapy #Small2026 #Expansion #Delivery #FormulationOptimization #Transposase #GeneTherapy #ClinicalExpansion* --- ### Post 3: AI 신약 — AlphaFold 4(DeepMind drug spin-off, Nature 2026) + AlphaFold 3 transformative review(Frontiers AI 2026) + AI/ML revolution drug discovery review(2026): AlphaFold 확장과 AI-driven drug discovery의 새 확장기 💊 **[AI 신약] AlphaFold 4(DeepMind drug spin-off, Nature 2026) + AlphaFold 3 transformative review(Frontiers AI 2026) + AI/ML drug discovery systematic review(2026): AlphaFold의 새 확장 — AI-driven drug discovery의 새 시대 개막** AI-driven drug discovery의 **확장**이 세 논문에서 동시에 보고된다. Callaway(Nature 2026), Chakraborty et al.(Frontiers AI 2026), Aljassim et al.(2026)의 논문이 각각 다른 축을 제시한다[4][5][6]. **AlphaFold 4: DeepMind drug spin-off의 exclusive new AI[4]**: (1) **DeepMind drug spin-off**: Isomorphic Labs 인접/관련 spin-off에서 개발. (2) **과학자들의 반응**: "An AlphaFold 4" — 기존 AlphaFold 시리즈를 능가하는 것으로 평가. (3) **exclusive 접근**: 특정 파트너십 외 제한적 공개. (4) ** pharmaceutical applications**: drug discovery acceleration 위한 새로운 AI 체계. (5) **시장 의미**: DeepMind의 AI-driven pharmaceutical expansion. **AlphaFold 3 transformative review: 구조 생물학의 패러다임 전환[5]**: (1) **AF1→AF2→AF3 arsitektur evolution**: AF1(DNN), AF2(Evoformer), AF3(Pairformer). (2) **주요 진화**: single-chain → protein-ligand, protein-nucleic acid, protein-protein complexes 확장. (3) **AlphaFold Database(AFDB)**: 대규모 구조 데이터베이스로 translational research 가속. (4) **SBDD(Structure-Based Drug Discovery)**: drug-target binding 연구의 혁명적 도구. (5) **남은 도전**: protein dynamics modeling, multiple conformational states prediction. (6) **향후**: biotechnology and medicine에서 지속적 혁신 예상. **AI/ML drug discovery systematic review: 53개 논문 분석[6]**: (1) **범위**: 2018-2026년 53개 논문. (2) **핵심 기술**: graph neural networks, transformers, reinforcement learning. (3) **적용 범위**: de novo molecular generation, molecular property prediction, target recognition, QSAR. (4) **AlphaFold 역할**: accurate protein structure prediction → drug-target binding exploration. (5) **시간/비용 절감**: drug discovery timeline years → months로 축소 가능성. (6) **현재 한계**: interpretability 부족, data limitations, regulatory approval 부재. (7) **AI clinical examples**: 성공 사례 보고. **7월 6일 IMPACT Framework + FDA AI Guidance 3-way convergence vs 오늘의 차별점**: 7/6이 **IMPACT + FDA AI Guidance + Pharma AI Multi-Modal Screening의 3-way convergence**를 제시했다면, 오늘은 그와 다른 축 — **AlphaFold의 새 확장(AlphaFold 4 발표 + AlphaFold 3 transformative review)**과 **AI/ML drug discovery의 종합적 review**를 통해 **AI-driven drug discovery의 새 확장기**를 동시에 제시한다. 3-way convergence(7/6) → AlphaFold 새 확장 + AI/ML 종합(7/7). 실무 함의: 약물 발견팀에서 AlphaFold 4의 pharmaceutical applications 가능성을 탐색하고, AlphaFold 3 review의 architecture evolution을 이해하여 drug-target binding 연구 전략을 수립해야 한다. AI/ML drug discovery 검토 시 Aljassim et al.의 systematic review를 참조하여 AI 적용의 실제적 한계와 가능성을 정확히 평가해야 한다. *출처: [AlphaFold 4 DeepMind spin-off Nature 2026](https://consensus.app/papers/details/30239e12756b5c63ab7b87a66091fe4b/), [AlphaFold 3 Transformative Chakraborty Front AI 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/), [AI ML Drug Discovery Aljassim Saudi J Med Pharm Sci 2026](https://consensus.app/papers/details/f3ca935ae2a85b829089520e055d67ba/), [AI ML Pharma Review Aljassim 2026](https://consensus.app/papers/details/f3ca935ae2a85b829089520e055d67ba/)* *#AlphaFold4 #AlphaFold3 #DeepMind #IsomorphicLabs #DrugDiscovery #AIDrugDiscovery #MachineLearning #GraphNeuralNetwork #Transformer #ReinforcementLearning #StructurePrediction #SBDD #FrontiersAI #Nature2026 #Expansion #Pharmaceutical #ClinicalTranslation #SystematicReview #QSAR #MolecularGeneration #ExpansionEra* --- ### Post 4: 단백질 AI — ROCKET 산업 이행 + AlphaFold 4 발표 + viral proteome Ab Initio analysis: 구조 예측 확장의 산업적 적용과 신규 영역开拓 🔬 **[단백질 AI] ROCKET(AlphaFold+cryoEM 통합, Nat Methods 2026) + AlphaFold 4(DeepMind drug spin-off, Nature 2026) + Viral proteome Ab initio structural analysis(Ali, Methods Mol Biol 2026): 구조 예측 확장의 산업적 적용과 신규 영역开拓** 단백질 AI의 **확장**이 세 논문에서 동시에 확인된다. Fadini et al.(Nat Methods 2026), Callaway(Nature 2026), Ali et al.(Methods Mol Biol 2026)의 논문이 각각 다른 축을 제시한다[7][4][8]. **ROCKET: 산업적 적용의 확장[7]**: (1) **AlphaFold2의 cryoEM/cryoET/X-ray 통합**: coevolutionary embeddings 공간에서 최적화. (2) **Industrial applicability**: low signal-to-noise ratio에서 특히 효과적, 재학습 불필요 automated model building. (3) **cryo-EM 장비 접근성 증가**: industrial 적용 가속. (4) **확장성**: 자동화된 구조 결정의 산업적流程 확립. **AlphaFold 4: pharmaceutical expansion[4]**: (1) **DeepMind drug spin-off**: pharmaceutical applications 위한 새로운 AI 체계. (2) **Exclusive AI**: drug discovery acceleration 특화. (3) **시장 확장**: AI-driven pharmaceutical research의 새 단계. **Viral proteome Ab initio structural analysis[8]**: (1) **Intrinsically disordered regions**: NMR/cryo-EM으로完全caputure 어려움. (2) **AlphaFold modeling**: near-experimental-quality atomic structures 생성. (3) **비교 framework**: reference structure bridging + structural deviations assessment. (4) **적용**: functional annotation, interaction understanding, viral protein evolution. (5) **핵심**: AI-driven structural analysis로 신규 영역(inherently disordered viral proteins) 확장. **7월 6일 Computational-Experimental Bridging + AlphaFold3 review vs 오늘의 차별점**: 7/6이 **ROCKET + AlphaFold3 review + PPI Atlas의 convergence**를 제시했다면, 오늘은 그와 다른 축 — **AlphaFold 4의 pharmaceutical spin-off 발표**와 **viral proteome Ab initio analysis로 신규 영역 확장**을 동시에 제시한다. Convergence(7/6) → pharmaceutical expansion + 신규 영역开拓(7/7). 실무 함의: 구조생물학팀에서 ROCKET의 cryoEM 통합을 활용하여 AlphaFold 예측의 한계를 보완하고, 바이러스 연구팀에서 Ali et al.의 Ab initio analysis를 활용하여 inherently disordered viral proteins 연구를 확장해야 한다. *출처: [ROCKET Fadini Nat Methods 2026](https://consensus.app/papers/details/a1a4ffbc5dd75c548e55837812a33916/), [AlphaFold 4 Callaway Nature 2026](https://consensus.app/papers/details/30239e12756b5c63ab7b87a66091fe4b/), [Viral Proteome AbInitio Ali Methods Mol Biol 2026](https://consensus.app/papers/details/79b57ecbdee05861904af02533ea870d/), [AlphaFold 3 Review Chakraborty Front AI 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/)* *#ROCKET #AlphaFold4 #AlphaFold #DeepMind #ViralProteome #AbInitio #StructuralBiology #CryoEM #CryoET #Expansion #Pharmaceutical #DrugDiscovery #IntrinsicallyDisordered #ViralEvolution #ProteinStructure #MethodsMolecularBiology #NatMethods #IndustrialApplication #NewFrontiers* --- ### Post 5: 세포 치료 & 재생의학 — Hypoimmune iPSC(CRISPR으로 HLA 제거, Stem Cell Res Ther 2026) + Base/Prime editing efficiency expansion(Advanced Science 2026): 범용 세포 치료 확장의 실증 🧫 **[세포 치료] Hypoimmune iPSC(CRISPR으로 HLA class I/II 제거 + immune-tolerant molecules 유지, Wu Stem Cell Res Ther 2026) + Prime editing efficiency expansion(Yu Advanced Science 2026) + CRISPR monitoring(Freedman Nat Rev Genet 2026): 범용 세포 치료 확장과 genome editing safety monitoring** 세포 치료/재생의학의 **확장**이 세 논문에서 동시에 보고된다. Wu et al.(Stem Cell Res Ther 2026), Yu et al.(Advanced Science 2026), Freedman et al.(Nat Rev Genet 2026)의 논문이 각각 다른 축을 제시한다[9][10][11]. **Hypoimmune iPSC: 범용 세포 치료의 확장이자 CRISPR 통합[9]**: (1) **CRISPR/Cas9로 hypoimmunogenic iPSCs**: HLA class I/II 제거 + immune-tolerant molecules(HLA-E, HLA-G, CD47) 유지. (2) **Universal 적용 가능성**: 개인 간 이식 가능. (3) **MSC-derived exosomes**: graft-versus-host disease + autoimmune reactions 감소. (4) **Immune checkpoint modulators(PD-L1)**: T-cell activation 억제, regulatory T-cell expansion 촉진, macrophage polarization 조절. (5) **남은 도전**: genomic instability + tumorigenic risk(유전자 편집 + 장기 세포 배양 중). (6) **미래 기술**: base editing + prime editing으로 DSB-induced chromosomal rearrangements 최소화. (7) **AI 통합**: AI-based immune profiling + precision genome editing + 3D bioprinting. (8) **핵심 의미**: 범용 세포 치료로 previously untreatable 질환 치료 가능. **Prime editing efficiency expansion[10]**: (1) **현재 한계**: low editing efficiency + limited capacity for large-scale manipulation. (2) **개선 연구**: PE efficiency 향상 + capability expansion 위한 지속적 연구. (3) **80% rare diseases**: genetic mutations로 발생. (4) **CRISPR-Cas9→Base editing→Prime editing**: genome editing technology evolution. (5) **DSB-free precise editing**: base editing(점변이) → prime editing(삽입, 결실, 모든 점변이). (6) **향후 방향**: efficiency + capacity 개선. **CRISPR genome editing monitoring[11]**: (1) **Preclinical-to-clinical toolkit**: genome editor의 safety/efficacy 평가. (2) **측정 계층**: direct DNA measurement → microphysiological systems → non-invasive in vivo imaging. (3) **On/off-target outcomes**: functional responses 이해 위한 essential benchmarks. (4) **Microphysiological systems**: organoids + organs-on-chips로 phenotypic evaluation. (5) **Non-invasive imaging**: biodistribution + edited cell activities 추적. (6) **핵심**: 임상 이행의 safety 관점에서 확장. **7월 6일 Cas9 Delivery 통합 + CRISPR 임상 데이터 후속 vs 오늘의 차별점**: 7/6이 **Cas9 delivery 기술들의 cross-domain bridging**을 제시했다면, 오늘은 그와 다른 축 — **hypoimmune iPSC로 범용 세포 치료 확장**(CRISPR 통합) + **prime editing efficiency expansion** + **genome editing monitoring toolkit**을 통해 **세포 치료 확장의 새 패러다임**을 동시에 제시한다. Delivery bridging(7/6) → 세포 치료 확장 + safety monitoring(7/7). 실무 함의: 세포 치료 개발팀에서 Wu et al.의 hypoimmune iPSC 전략을 참조하여 범용 세포 치료 플랫폼을 설계해야 한다. 유전체 편집 플랫폼팀에서 Yu et al.의 prime editing efficiency 개선 연구를 추적하고, genome editing monitoring toolkit(Freedman)을 활용하여 임상 이전 safety 평가 체계를 구축해야 한다. *출처: [Hypoimmune iPSC Wu Stem Cell Res Ther 2026](https://consensus.app/papers/details/1cba919e589f54adaa8363be5f6ee23b/), [Prime Editing Efficiency Yu Advanced Science 2026](https://consensus.app/papers/details/475fc3cbbe805f5e915626f08d2da039/), [CRISPR Monitoring Freedman Nat Rev Genet 2026](https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/), [Base Editing Review Aliciaslan J Cell Mol Med 2026](https://consensus.app/papers/details/02421a2246d0589bade65d0603abde01/)* *#Hypoimmune #iPSC #CRISPR #HLA #UniversalCellTherapy #StemCell #RegenerativeMedicine #PrimeEditing #BaseEditing #Expansion #Efficiency #Genomelnstability #SafetyMonitoring #ClinicalTranslation #GvHD #ImmuneTolerance #CD47 #HLAE #HLAG #Microphysiological #Organoids #OrgansOnChip #Expansion #TherapeuticExpansion #GenomeEditing* --- ### Post 6: FDA/규제 — State preemption + AI medical device oversight(Health Affairs Scholar 2026) + AI agent regulation(NPJ Digital Med 2026): FDA AI 규제 확장의 새로운 프레임워크 ⚖️ **[FDA/규제] State preemption + AI medical device oversight(Health Affairs Scholar 2026) + AI agent regulation: Unconfined Non-Deterministic Clinical Software(UNDCS, NPJ Digital Med 2026): FDA AI 규제 확장의 새로운 프레임워크와 federal-state regulatory 확장** FDA/규제의 **확장**이 두 논문에서 동시에 진행된다. Thomason et al.(Health Affairs Scholar 2026), Tan et al.(NPJ Digital Med 2026)의 논문이 각각 다른 축을 제시한다[12][13]. **State preemption: AI medical device oversight의 역사적 교훈[12]**: (1) **1976 MDA analogy**: Medical Device Amendments의 preemption 조항 → state-level fragment 문제 해결. (2) **현재 문제**: states이 broad, inconsistent regulatory schemes 전개 → AI-enabled medical devices가 consumer-protection frameworks에 포함. (3) **위험**: 1976년 이전의 fragmented device landscape 재현 가능성. (4) **제안**: health care-related AI에 제한된 preemption clause + modernized flexible federal oversight framework. (5) **핵심**: FDA의 technical expertise 기반 federal product oversight. (6) ** 患者/의사/기업 혜택**: regulatory clarity, reduced compliance fragmentation, supportive environment. **AI agent regulation: Unconfined Non-Deterministic Clinical Software[13]**: (1) **LLM-based CDS**: clinical decision support 출력의 regulated medical device criteria 충족 여부. (2) **구분**: confined vs unconfined AI systems. (3) **기존 guidelines로 address된 항목**: 일부 considerations는 기존 framework로 대응 가능. (4) **새로운 규제 필요 영역**: "generalized" CDSS(특정 임상 적응증에 anchor되지 않음). (5) **위험 완화 전략**: 새로운 guidelines에 포함 가능한 구체적 영역. (6) **핵심**: AI agent 규제 확장의迫切적 필요성. **7월 6일 IMPACT Translation Axis + FDA AI Guidance gap analysis + Global harmonization convergence vs 오늘의 차별점**: 7/6이 **academia-regulatory convergence의 실질적 이행**을 제시했다면, 오늘은 그와 다른 축 — **federal-state regulatory framework 확장**(state preemption analogy)과 **AI agent(UNDCS) 규제 확장**을 동시에 제시한다. Convergence(7/6) → federal-state regulatory framework expansion + AI agent regulation(7/7). 실무 함의: 규제팀에서 Thomason et al.의 state preemption framework 논의를 참조하여 federal-state regulatory framework 확장에 대비해야 한다. AI agent/CDSS 개발팀에서 Tan et al.의 UNDCS 규제 분석을 참조하여 generalized AI systems의 규제 위험을 선제적으로 평가해야 한다. *출처: [State Preemption AI Medical Devices Thomason Health Affairs Scholar 2026](https://consensus.app/papers/details/c4883fd893a05eacbe341dfeb9b883d7/), [AI Agents Regulation Tan NPJ Digital Med 2026](https://consensus.app/papers/details/4c1c273abef15027ae93c2cc8193af70/), [GenAI Regulation Ong NPJ Digital Med 2026](https://consensus.app/papers/details/080f0aab9c7f5d80aa812978184ceea8/)* *#FDA #StatePreemption #AIMedicalDevice #Regulation #UNDCS #UnconfinedAI #ClinicalDecisionSupport #HealthAffairsScholar #NPJDigitalMedicine #FederalFramework #Expansion #Compliance #Fragmentation #1976MDA #Preemption #AIFramework #RegulatoryExpansion #ClinicalSoftware #Governance* --- ### Post 7: Spatial Transcriptomics & Pan-Cancer — MONSTAR-SCREEN-3(331 tumors, 21 types, ~20M cells, Xenium 5K, AACR 2026) + TAM atlas(28 subtypes, 16 cancer types, 291 samples, Cell Discovery 2026) + PROSPECTS(415 patients, 6 cancers, 4.4M cells, spatial proteomics, AACR 2026): 공간 전사체 확장의 산업 표준 수립 🗺️ **[Spatial Transcriptomics/Pan-Cancer] MONSTAR-SCREEN-3(331 tumors, 21 solid types, ~20M cells, Xenium 5K, AACR 2026) + TAM atlas(28 subtypes, 16 cancer types, 291 samples, Cell Discovery 2026) + PROSPECTS(415 patients, 6 major malignancies, 4.4M cells, spatial proteomics, AACR 2026): 공간 전사체/단백질 확장의 산업 표준 수립과 임상 biomarker 확장의 三.axis** 공간 전사체/단백질 분석의 **확장**이 세 논문에서 동시에 보고된다. Imai et al.(AACR 2026), Nie et al.(Cell Discovery 2026), Huynh et al.(AACR 2026)의 논문이 각각 다른 축을 제시한다[14][15][16]. **MONSTAR-SCREEN-3: 21개 고형암 ~2천만 개 세포의 공간 아틀라스[14]**: (1) **SCRUM-Japan MONSTAR-SCREEN**: nationwide molecular profiling, all solid tumors(hematologic malignancy 제외). (2) **M3 project**: spatial transcriptomics 통합으로 "quantum leap" 추구. (3) **규모**: 331 FFPE tumors, 21 solid tumor types, ~20 million cells. (4) **플랫폼**: Xenium 5K + standardized NCCE-GxD workflow. (5) **15개 conserved pan-cancer cellular niches**: distinct compositions + spatial architectures. (6) **MC9(innate-immune-rich interface)**: advanced-stage tumors에 enriched, poor prognosis 연관. (7) **MC10/MC14(lymphocyte-dominant)**: favorable outcomes + immunotherapy response 연관. (8) **TLS formation**: secondary follicle signatures → improved prognosis + immunotherapy response. (9) **핵심:Conserved pan-cancer spatial ecosystem archetypes 확립**. **TAM atlas: 28개 subtypes, 16개 암종[15]**: (1) **Pan-cancer TAM subtypes**: 28개 TAM subtypes 동정. (2) **규모**: 291개 human samples, 16개 cancer types. (3) **공간 분포**: peritumoral vs core regions → angiogenesis + metabolic reprogramming. (4) **CD8+ T cell retention**: TAMs가 local inflammation 유도 → immunosuppressive microenvironment. (5) **CAFs-TAMs interplay**: polarization, survival, recruitment, activation. (6) **SPP1 + integrin/CD44 axis**: CAFs-TAMs tumor invasion/metastasis/immune evasion mediation. (7) **치료 타겟 가능성**: specific TAM subpopulations 위한 치료 전략 수립 가능. **PROSPECTS: 6개 악성 종양 415개 환자 spatial proteomics[16]**: (1) **PROSPECTS initiative**: pan-cancer spatial proteomic atlas. (2) **규모**: 415 patients, 6 major malignancies(HN SCC, Lung, TNBC, Ovarian, Colorectal, HCC), >1,000 tissue cores, >4.4 million cells. (3) **30-plex Phenocycler**: 15 major cell types at single-cell resolution. (4) **TNBC**: Tumor Cell-Neutrophil interactions = strongest adverse prognostic feature(P=0.00001). (5) **Lung**: vascular-immune + stromal-tumor interfaces key — endothelial-Macrophage(P=0.0003), Fibroblast-Tumor Cell(P=0.002). (6) **Conserved spatial signatures**: recurrent fibroblast-tumor cell interface motif across malignancies. (7) **Complex spatial syntax**: higher-order interactions > simple pairwise for prognosis. (8) **치료 타겟**: spatially resolved cellular interaction networks = new class of clinically actionable biomarkers. **7월 6일 Pan-Cancer TME + Prostate + Gastric Atlas convergence vs 오늘의 차별점**: 7/6이 **Pan-Cancer TME + Prostate + Gastric Atlas의 통합**을 제시했다면, 오늘은 그와 다른 축 — **MONSTAR-SCREEN-3의 산업 표준 확립**(Xenium 5K + standardized workflow + 20M cells), **TAM atlas의 세포 유형 확장**(28 subtypes, spatial distribution mechanism), **PROSPECTS의 공간 단백질 확장**(spatial proteomics + multi-scale computational pipeline + higher-order interactions)을 동시에 제시한다. Atlas convergence(7/6) → 산업 표준 확립 + 세포 유형 확장 + spatial proteomics 확장(7/7). 실무 함의: 면역종양학팀에서 MONSTAR-SCREEN-3의 MC9/MC10/MC14 niche 아키텍처를 참조하여 immunotherapy response biomarker 개발 전략을 수립해야 한다. TAM 연구팀에서 Nie et al.의 28개 TAM subtypes와 SPP1-integrin/CD44 axis를 활용하여 specific TAM subpopulation 타겟 전략을 수립해야 한다. PROSPECTS团队的에서 Huynh et al.의 higher-order spatial interactions를 참조하여 multi-scale biomarker 개발 전략을 추진해야 한다. *출처: [MONSTAR-SCREEN-3 AACR 2026](https://consensus.app/papers/details/acaee5f0a8c55ba89f5719ee65eaba95/), [TAM Atlas Nie Cell Discovery 2026](https://consensus.app/papers/details/cae4940d39b251569b9f7f6e65465aad/), [PROSPECTS Huynh AACR 2026](https://consensus.app/papers/details/891483eff3a7519f864aacc462b48045/), [Pan-Cancer TSME Li Cell Rep Med 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)* *#MONSTAR-SCREEN #SpatialTranscriptomics #Xenium5K #TAMAtlas #PROSPECTS #SpatialProteomics #PanCancer #TME #Niche #CellDiscovery #AACR2026 #21TumorTypes #20MillionCells #28Subtypes #16CancerTypes #Phenocycler #HigherOrderInteractions #TNBC #LungCancer #OvarianCancer #ColorectalCancer #HCC #Expansion #IndustrialStandard #Biomarker #Immunotherapy #TLS #MC9 #MC10 #SpatialEcosystem* --- ### Post 8: 오늘의 요약 — 7월 7일 확장의 날 🧬 **7월 7일 확장의 날 — 6개 전선 요약** 7월 7일은 **확장의 날(Expansion Day)**이다. 6개 전선이 각각 통합된 기준들이 산업 전반으로 확장되는 날을 보여준다. **전선 1: CRISPR Delivery 확장 실증** — LNP compositional optimization(>80% knockout), hybrid piggyBac+AAV+LNP(100배 dose reduction), PEG-free organic solvent-free LNP(extravascular/extrahepatic targeting)로 CRISPR delivery 확장 가능성의 산업적 실증 동시 진행[1][2][3]. **전선 2: AlphaFold 확장의 새 시대** — AlphaFold 4(DeepMind drug spin-off, exclusive pharmaceutical AI, Nature)와 AlphaFold 3 transformative review(architectural evolution + SBDD revolution) + AI/ML systematic review(53개 논문) 동시 발표[4][5][6]. **전선 3: 단백질 AI 산업 적용 확장** — ROCKET의 industrial applicability + AlphaFold 4의 pharmaceutical expansion + viral proteome Ab initio structural analysis로 구조 예측의 산업적 확장 + 신규 영역(inherently disordered viral proteins) 동시开拓[7][4][8]. **전선 4: Hypoimmune iPSC로 범용 세포 치료 확장** — CRISPR으로 HLA class I/II 제거 + immune-tolerant molecules 유지하는 hypoimmune iPSC + base/prime editing으로 genomic safety 개선 + genome editing monitoring toolkit(Freedman Nat Rev Genet)으로 임상 이전 safety 체계 확립[9][10][11]. **전선 5: FDA AI 규제 프레임워크 확장** — state preemption analogy로 federal AI device oversight framework 확장 + AI agent(UNDCS) regulation으로 generalized AI CDSS 규제 확장[12][13]. **전선 6: 공간 전사체/단백질 확장의 산업 표준 수립** — MONSTAR-SCREEN-3(331 tumors, 21 types, ~20M cells, Xenium 5K 산업 표준) + TAM atlas(28 subtypes, 16 cancer types, spatial distribution mechanism) + PROSPECTS(415 patients, 6 cancers, 4.4M cells, spatial proteomics, higher-order interactions)[14][15][16]. 확장은 통합의 다음 단계다. 오늘의 6개 전선은 그 순자의 열한 번째 단계에 있다. 내일(7월 8일 수요일) 바라볼 세 지점: AlphaFold 4의 구체적 pharmaceutical applications 공개 여부, hypoimmune iPSC의 임상 전환 진행 상황, MONSTAR-SCREEN-3의 임상적용 사례. 확장 다음은 **실행(Execution)**이다. 오늘의 6개 전선이 제시하는 공통 질문: 확장된 기술들이 각 분야主流 체계에서 어떤 방식으로 실행(Execution)되어야 하는가. 이 질문이 내일 이후 각 전선의 핵심 과제가 된다. *출처: [LNP Optimization Jiang Small 2026](https://consensus.app/papers/details/88fb6c79e4d859f389cdf3480a9815be/), [Hybrid piggyBac Xu Molecular Therapy 2026](https://consensus.app/papers/details/0c2389f227c5528993ce96984aeb2036/), [Extrahepatic LNP Streiber Small 2026](https://consensus.app/papers/details/1ba8360a176b5f83913089048aa90b2e/), [AlphaFold 4 Callaway Nature 2026](https://consensus.app/papers/details/30239e12756b5c63ab7b87a66091fe4b/), [AlphaFold 3 Chakraborty Front AI 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/), [ROCKET Fadini Nat Methods 2026](https://consensus.app/papers/details/a1a4ffbc5dd75c548e55837812a33916/), [Viral Proteome Ali Methods Mol Biol 2026](https://consensus.app/papers/details/79b57ecbdee05861904af02533ea870d/), [Hypoimmune iPSC Wu Stem Cell Res Ther 2026](https://consensus.app/papers/details/1cba919e589f54adaa8363be5f6ee23b/), [Prime Editing Yu Advanced Science 2026](https://consensus.app/papers/details/475fc3cbbe805f5e915626f08d2da039/), [CRISPR Monitoring Freedman Nat Rev Genet 2026](https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/), [State Preemption Thomason Health Affairs Scholar 2026](https://consensus.app/papers/details/c4883fd893a05eacbe341dfeb9b883d7/), [AI Agents Tan NPJ Digital Med 2026](https://consensus.app/papers/details/4c1c273abef15027ae93c2cc8193af70/), [MONSTAR-SCREEN-3 AACR 2026](https://consensus.app/papers/details/acaee5f0a8c55ba89f5719ee65eaba95/), [TAM Atlas Nie Cell Discovery 2026](https://consensus.app/papers/details/cae4940d39b251569b9f7f6e65465aad/), [PROSPECTS Huynh AACR 2026](https://consensus.app/papers/details/891483eff3a7519f864aacc462b48045/)* *#AIBioresearch #ExpansionDay #BioResearchDaily #July2026 #LNPOptimization #AlphaFold4 #DeepMind #Pharmaceutical #Hypoimmune #iPSC #UniversalCellTherapy #MONSTAR-SCREEN #TAMAtlas #PROSPECTS #SpatialTranscriptomics #SpatialProteomics #Xenium5K #21TumorTypes #20MillionCells #28Subtypes #StatePreemption #UNDCS #AIRegulation #Expansion #Delivery #DoseReduction #ClinicalTranslation #IndustrialStandard #Execution #Convergence* --- ## Sources 1. Jiang J, et al. Compositional Optimization of CRISPR/Cas9 Lipid Nanoparticles for Efficient Knockdown of Target Genes. Small. 2026. https://consensus.app/papers/details/88fb6c79e4d859f389cdf3480a9815be/ 2. Xu R, et al. A hybrid piggyBac AAV-transposon and LNP-transposase for treating arginase deficiency: A 100-fold dose reduction compared to AAV alone. Mol Ther. 2026. https://consensus.app/papers/details/0c2389f227c5528993ce96984aeb2036/ 3. Streiber M, et al. Extrahepatic Gene Editing In Vivo Using Organic Solvent-Free Lipid Nanoparticles. Small. 2026. https://consensus.app/papers/details/1ba8360a176b5f83913089048aa90b2e/ 4. Callaway E. 'An AlphaFold 4' — scientists marvel at DeepMind drug spin-off's exclusive new AI. Nature. 2026. https://consensus.app/papers/details/30239e12756b5c63ab7b87a66091fe4b/ 5. Chakraborty C, et al. The transformative impact of AI-enabled AlphaFold 3: evolution, current status, and future prospects in structural biology. Front Artif Intell. 2026. https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/ 6. Aljassim ZG, et al. The Role of Artificial Intelligence and Machine Learning in Revolutionizing Drug Discovery and Pharmacological Research: A Systematic Review. Saudi J Med Pharm Sci. 2026. https://consensus.app/papers/details/f3ca935ae2a85b829089520e055d67ba/ 7. Fadini A, et al. AlphaFold as a prior: experimental structure determination conditioned on a pretrained neural network (ROCKET). Nat Methods. 2026. https://consensus.app/papers/details/a1a4ffbc5dd75c548e55837812a33916/ 8. Ali MA, et al. Proteome-wide Ab Initio Structural Analysis of Viral Evolution. Methods Mol Biol. 2026. https://consensus.app/papers/details/79b57ecbdee05861904af02533ea870d/ 9. Wu X, et al. Immune-evasive stem cells: engineering tolerance and reprogramming microenvironments for regenerative therapy. Stem Cell Res Ther. 2026. https://consensus.app/papers/details/1cba919e589f54adaa8363be5f6ee23b/ 10. Yu J, et al. Evolution of Prime Editing: Enhancing Efficiency and Expanding Capacity. Adv Sci. 2026. https://consensus.app/papers/details/475fc3cbbe805f5e915626f08d2da039/ 11. Freedman BS, et al. Monitoring biological effects of somatic cell genome editing. Nat Rev Genet. 2026. https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/ 12. Thomason C, et al. The history of state preemption and medical device regulation: lessons for artificial intelligence oversight. Health Affairs Scholar. 2026. https://consensus.app/papers/details/c4883fd893a05eacbe341dfeb9b883d7/ 13. Tan C, et al. Regulation of clinical Artificial Intelligence (AI) in the Age of Agents: Unconfined Non-Deterministic Clinical Software (UNDCS) systems for healthcare. NPJ Digital Med. 2026. https://consensus.app/papers/details/4c1c273abef15027ae93c2cc8193af70/ 14. Imai M, et al. The MONSTAR-SCREEN-3 Spatial Atlas: Pan-cancer TME archetypes and clinically relevant tumor-immune ecosystems. Cancer Res. 2026. https://consensus.app/papers/details/acaee5f0a8c55ba89f5719ee65eaba95/ 15. Nie R, et al. Spatial single-cell landscape of tumor-associated macrophages and their crosstalk with the tumor microenvironment. Cell Discovery. 2026. https://consensus.app/papers/details/cae4940d39b251569b9f7f6e65465aad/ 16. Huynh KLA, et al. Defining spatial biomarkers of survival across solid tumors using a pan-cancer proteomics atlas. Cancer Res. 2026. https://consensus.app/papers/details/891483eff3a7519f864aacc462b48045/
Research Pulse·2026-07-07
Research Pulse — 2026-07-07
28 journals × 7 topics · fibrosis · OXPHOS · ferroptosis · sarcopenia · senescence
Raw data + scoring: Daily Tech Digest (separate feed)
Request a Paid Brief